Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 7, 2014; 20(41): 15310-15318
Published online Nov 7, 2014. doi: 10.3748/wjg.v20.i41.15310
Published online Nov 7, 2014. doi: 10.3748/wjg.v20.i41.15310
Therapeutic effect of a hydroxynaphthoquinone fraction on dextran sulfate sodium-induced ulcerative colitis
Zi-Liang Zhang, Ke Liu, College of Life Science, Jilin University, Changchun 130012, Jilin Province, China
Hua-Ying Fan, Ming-Yan Yang, Zuo-Kai Zhang, Ke Liu, School of Pharmacy, Yantai University, Yantai 264005, Shandong Province, China
Ming-Yan Yang, Ke Liu, Shandong Target Drug Research Co. Ltd., Yantai 264005, Shandong Province, China
Author contributions: Zhang ZL, Fan HY and Liu K designed the research; Zhang ZL, Yang MY and Zhang ZK performed the research; Zhang ZL analyzed the data and wrote the paper.
Supported by Programs for Science and Technology Development and Plan of Yantai, No. 2013ZH086
Correspondence to: Ke Liu, MD, College of Life Science, Jilin University, No. 2699 Qianjin Street, Changchun 130012, Jilin Province, China. liuke201116@163.com
Telephone: +86-535-6706066 Fax: +86-535-6706066
Received: May 20, 2014
Revised: June 21, 2014
Accepted: July 16, 2014
Published online: November 7, 2014
Revised: June 21, 2014
Accepted: July 16, 2014
Published online: November 7, 2014
Core Tip
Core tip: There is an urgent need for effective and safe therapeutic approaches for the treatment of inflammatory bowel disease. We obtained a hydroxynaphthoquinone mixture (HM) from Zicao. Previously, HM demonstrated a favorable therapeutic effect in 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis. To exclude that the therapeutic effect was limited to TNBS-induced colitis, we evaluated the effect of HM in dextran sulfate sodium (DSS)-induced colitis. Similarly, we found that HM was beneficial in DSS-induced colitis. The underlying mechanism may be associated with the regulation of tumor necrosis factor-α level and nuclear factor-κB activity. These findings provide support for further development of HM for clinical applications.